Fly News Breaks for February 24, 2020
Feb 24, 2020 | 09:16 EDT
William Blair analyst Myles Minter initiated coverage of Neurocrine Biosciences with an Outperform rating and $116 fair value estimate. The company is a leader in neurology, developing and marketing Ingrezza for the treatment of tardive dyskinesia, which currently annualizes more than $800M per year, Minter tells investors in a research note. Further, Neurocrine management has strategically deployed capital from Ingrezza free cash flow to build an "impressive" pipeline for long-term growth, contends the analyst.
News For NBIX From the Last 2 Days
There are no results for your query NBIX